Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alirocumab (Praluent) vs Nicotinamide Riboside: Nicotinamide Riboside has the stronger overall evidence (5.5 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Nicotinamide Riboside wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
any
Subcutaneous prefilled pen/syringe (alirocumab)
300–500 mg daily
Morning with breakfast, Split dosing (morning and midday) for doses above 500 mg
Nicotinamide Riboside Chloride capsules or powder
Within weeks
Months to years
Years
At each injection
1–2 weeks
4–8 weeks
8–16 weeks
4–8 weeks
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Journal of cachexia, sarcopenia and muscle (2025) · Meta analysis
Systematic review and meta-analysis of RCTs evaluating NMN and NR effects on skeletal muscle mass and function
NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Ageing research reviews (2026) · Systematic review
PRISMA-guided systematic review of both preclinical and clinical NAD+ supplementation literature
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
Experimental gerontology (2020) · Systematic review
Systematic review of 147 articles (113 preclinical, 34 clinical) on NAD+ precursor therapy
Based on 8-week RCT showing dose-dependent increases of 22%, 51%, and 142% at 100, 300, and 1000mg respectively. Individual response varies significantly (30% show variable response). NR-SAFE trial confirmed safety up to 2000mg.
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide Riboside has a higher evidence score (5.5/10 vs 4.5/10) and wins in 3 of 3 categories.
For support heart health, Alirocumab (Praluent) has a higher relevance score (80 vs 62).
No known interactions between Alirocumab (Praluent) and Nicotinamide Riboside have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.